Search clinical trials for: EZN-2208

Total 755 results

Enzon Pharmaceuticals, Inc.

Completed

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)

Lymphoma | Advanced Solid Tumors

United States
Enzon Pharmaceuticals, Inc.

Completed

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)

Lymphoma | Advanced Solid Tumors

United States
Enzon Pharmaceuticals, Inc.

Terminated

A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer (PEG-SN38)

Metastatic Breast Cancer

United States
Enzon Pharmaceuticals, Inc.

Terminated

Study of EZN-2208 Pediatric Patients With Solid Tumors

Solid Tumors

United States
National Cancer Institute (NCI)

Completed

EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors

Neoplasms

United States
Enzon Pharmaceuticals, Inc.

Unknown

A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

Metastatic Colorectal Cancer

United States, Canada, Israel, Netherlands, United Kingdom
NVP Healthcare

Completed

To Evaluate the Safety and the Pharmacokinetics of NVP-2203

Healthy Volunteers

Korea, Republic of
NVP Healthcare

Recruiting

To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients

Cardiovascular Diseases

Korea, Republic of
Samik Pharmaceutical Co. Ltd.

Completed

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of SIPS-2209-1 in Healthy Korean Volunteers

Healthy

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

United States
Merck Sharp & Dohme LLC

Completed

Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)

Neoplasms | Cancer | Metastatic Solid Tumors | Locally Advanced Tumors
Celgene

Completed

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Healthy

United States
Sierra Oncology, Inc.

Completed

A Study of PNT2258 in Patients With Advanced Solid Tumors

Melanoma | Lymphoma | Cancer | Prostate Cancer

United States
Ono Pharmaceutical Co. Ltd
Parexel

Completed

A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy Participants

Neurodegenerative Diseases

United Kingdom
Nguyen Thi Trieu, MD

Completed

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection (AntiCov-220)

Covid19

Vietnam
Chinese University of Hong Kong

Completed

MK-2206 in Recurrent Nasopharyngeal Carcinoma (MC1079)

Recurrent Nasopharyngeal Carcinoma

Hong Kong
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital; University... and other collaborators

Withdrawn

MK-2206 for Recurrent Malignant Glioma

Malignant Glioma

United States
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)

Hepatitis C
National Cancer Institute (NCI)

Completed

A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases

Neoplasms | Liver Metastases

United States
Vir Biotechnology, Inc.

Recruiting

A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

Renal Impairment

United States
Antiva Biosciences

Recruiting

A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia

Cervical Intraepithelial Neoplasia

Australia, South Africa
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Completed

Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

PANCREAS | Neuroendocrine

United States
Mylan Inc.
Theravance Biopharma

Completed

Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment

Renal Impairment

United States
Ono Pharmaceutical Co. Ltd

Recruiting

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Multiple System Atrophy (MSA)

United States
Mylan Inc.
Theravance Biopharma

Completed

A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Enzon Pharmaceuticals, Inc.

Completed

Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma

Lymphoma | Carcinoma

United States
Calithera Biosciences, Inc

Terminated

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Advanced Nonhematological Neoplasms

Korea, Republic of, Japan, Taiwan
Amgen

Terminated

Safety Study of AMG 228 to Treat Solid Tumors

Melanoma | Cancer | Colorectal Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Oncology | Tumors | Advanced Malignancy | Oncology Patients | Transitional Cell Carinoma of Bladder

Belgium, France, United States, Germany, Australia
Celgene

Completed

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

Healthy Volunteers

United States
Sanofi

Completed

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Influenza | Myxovirus Infection | Orthomyxoviruses

United States
Mylan Inc.
Theravance Biopharma

Completed

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Mylan Inc.
Theravance Biopharma

Completed

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Merck Sharp & Dohme LLC
AstraZeneca

Completed

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Locally Advanced or Metastatic Solid Tumors
Celgene

Completed

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Renal Insufficiency

United States
Celgene

Completed

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus

United States
Allon Therapeutics

Completed

Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

Mild Cognitive Impairment

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma... and other conditions

United States
Mylan Inc.
Theravance Biopharma

Completed

Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment

Hepatic Impairment

United States
Celgene

Withdrawn

A Phase 2 Study With CC-220 in Skin Sarcoidosis

Sarcoidosis
Inter-American Development Bank
Universidade Federal do Ceará; Municipal Secretary of Health, Fortaleza Brasil

Unknown

Evaluation of the Home Visiting Pilot Program on Early Childhood Outcomes in Fortaleza Brazil

Child Development
M.D. Anderson Cancer Center
Amgen

Withdrawn

AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer

United States
Celgene

Completed

Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

Healthy Volunteers | Hepatic Impairment

United States
Zeria Pharmaceutical

Completed

Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

Japan
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Belgium, Germany, Spain, Canada, Serbia, Colombia, Poland, Argentina, Brazil, Mexico, Hungary, France, Russian Federation, Italy
Calithera Biosciences, Inc

Terminated

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Squamous Non-small-cell Lung Cancer | NFE2L2 Gene Mutation | Squamous Non-Small Cell Neoplasm of Lung

United States
Mylan Inc.
Theravance Biopharma

Completed

TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

Chronic Obstructive Pulmonary Disease (COPD)

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza

Italy
Addpharma Inc.

Completed

A Study to Evaluate the Efficacy and Safety of AD-208

Androgenetic Alopecia

Korea, Republic of
Resverlogix Corp

Completed

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease (ASSERT)

Coronary Artery Disease | Atherosclerosis

United States
Jeil Pharmaceutical Co., Ltd.

Completed

Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets

Essential Hypertension

Korea, Republic of

Search clinical trials for: EZN-2208

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations